Wecare Probiotics Shares Insights from Clinical Trial on Lacticasibacillus Rhamnosus LRa05 for Pediatric Allergic Rhinitis

July 10, 2025 – In light of World Allergy Day and the recent World Allergy Week 2025, which highlighted the critical theme of Anaphylaxis, Wecare Probiotics would like to share insights from an ongoing clinical trial (NCT06699537) involving its flagship probiotic strain, Lacticasibacillus Rhamnosus LRa05. This study is exploring the potential of LRa05 to help alleviate symptoms of allergic rhinitis in children aged 4 to 12.

Allergic rhinitis, commonly known as hay fever, can significantly impact children's daily lives. Wecare Probiotics is dedicated to investigating innovative and natural approaches to support pediatric health.

The clinical trial for LRa05 aims to understand how this specific probiotic strain might reduce allergic rhinitis symptoms. Researchers are also examining the relationship between LRa05, changes in gut bacteria, and immune responses in the children participating in the study. This comprehensive approach seeks to provide valuable insights into the mechanisms by which LRa05 may offer benefits.

This trial represents a step forward in exploring treatment options for pediatric allergic rhinitis. We are keen to see how LRa05 may contribute to improving the well-being of children affected by this common allergic condition.